女性保留生殖器官根治性膀胱切除术与标准根治性膀胱切除术的对比:围手术期、肿瘤学与功能结局的荟萃分析与系统评价
该系统评价与荟萃分析纳入10项研究共2015例女性膀胱癌患者,比较保留生殖器官根治性膀胱切除术(ROPRC)与标准根治性膀胱切除术(SRC)。结果显示ROPRC显著缩短手术时间和术后禁食时间,并显著改善日间与夜间控尿率及性功能,而肿瘤学结局与SRC相当。结论认为ROPRC是可行且有效的替代方案,在不影响肿瘤治疗效果的前提下改善生活质量。
要点
- ROPRC显著缩短手术时间(MD -45.69,95%CI -78.91~-12.47,p=0.007)。
- ROPRC显著改善日间控尿率(OR 4.94)和夜间控尿率(OR 5.91)。
- ROPRC与SRC在肿瘤学结局(切缘阳性、复发、生存)方面无显著差异。
核心结论
- ROPRC是女性膀胱癌患者可行且有效的SRC替代方案,功能结局更优且肿瘤学安全性相似。
研究设计与样本
- 系统评价与累积荟萃分析,检索多个科学数据库(2023年11月),遵循PRISMA和AMSTAR指南,注册于PROSPERO(CRD42024501522)。
- 纳入10项研究,共2015例女性膀胱癌患者。
主要发现
- ROPRC组手术时间显著缩短(MD -45.69,95%CI -78.91~-12.47,p=0.007)。
- ROPRC组术后禁食时间显著缩短(MD -0.69,95%CI -1.25~-0.13,p=0.02)。
- ROPRC组日间控尿率显著提高(OR 4.94,95%CI 1.53~15.91,p=0.008)。
- ROPRC组夜间控尿率显著提高(OR 5.91,95%CI 1.94~18.01,p=0.002)。
- ROPRC组女性性功能指数(FSFI)评分显著改善(MD 5.72,95%CI 0.19~11.26,p=0.04)。
关键数值与推荐
- 估计失血量、住院时间、总体术后并发症、轻微并发症及严重并发症在ROPRC与SRC间无显著差异。
- 阳性手术切缘、肿瘤复发率、总生存、癌症特异性生存、无复发生存及无进展生存在两种术式间无显著差异。
临床怎么用
- 对于合适的女性膀胱癌患者,ROPRC可作为SRC的替代术式,以改善控尿和性功能而不影响肿瘤学安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the perioperative, oncological, and functional outcomes of reproductive organ-preserving radical cystectomy (ROPRC) compared to standard radical cystectomy (SRC) in the treatment of female bladder cancer. METHODS: A systematic search was conducted in November 2023 across several scientific databases. We executed a systematic review and cumulative meta-analysis of the primary outcomes of interest, adhering to the PRISMA and AMSTAR guidelines. The study was registered in PROSPERO (CRD42024501522). RESULTS: The meta-analysis included 10 studies with a total of 2015 participants. ROPRC showed a significant reduction in operative time and postoperative fasting period compared to SRC (MD - 45.69, 95% CI - 78.91 ~ - 12.47, p = 0.007, and MD - 0.69, 95% CI - 1.25 ~ - 0.13, p = 0.02, respectively). Functional outcomes, both daytime continence rate (OR 4.94, 95% CI 1.53 ~ 15.91, p = 0.008) and nighttime continence rate (OR 5.91, 95% CI 1.94 ~ 18.01, p = 0.002), and sexual function measured by the Female Sexual Function Index (MD 5.72, 95% CI 0.19 ~ 11.26, p = 0.04), were significantly improved in the ROPRC group. There were no significant differences between ROPRC and SRC in terms of estimated blood loss, length of hospital stay, overall postoperative complications, minor complications or major complications. Oncologically, both procedures showed comparable outcomes with no significant differences in positive surgical margins, tumor recurrence rates, overall survival, cancer-specific survival, recurrence-free survival, or progression-free survival. CONCLUSIONS: ROPRC is a viable and effective alternative to SRC in female bladder cancer patients, offering enhanced functional outcomes and similar oncological safety. These findings suggest that ROPRC can improve the quality of life in female bladder cancer patients without compromising the efficacy of cancer treatment.
引用
- You C, Cheng L, Fang Q, et al. Comparative evaluation of reproductive organ-preserving versus standard radical cystectomy in female: a meta-analysis and systematic review of perioperative, oncological, and functional outcomes. Surg Endosc. 2024. PMID: 39009729. doi:10.1007/s00464-024-11074-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。